R&D Services for Diabetes Mellitus and Diabetic Complications

R&D Services for Diabetes Mellitus and Diabetic Complications

With the improvement of living standards, the prevalence of diabetes is on the rise all over the world. It has become another non communicable chronic disease that seriously endangers human health. As a dedicated CRO company, Ace Therapeutics offers a full range of services related to diabetes.

What is Diabetes

The main types of diabetes include type 1 diabetes mellitus (T1DM), type 2 diabetes mellitus (T2DM), gestational diabetes (diabetes while pregnant) and other special types of diabetes. The T2DM is the main disease, accounting for about 95%.

  • Type 1 Diabetes Mellitus
    T1DM is a genetic and immune disruption autoimmune disease that results in massive β-cell destruction. It is recognized to result from a complex interplay between environmental factors and microbiome, genome, metabolism, and immune systems that vary between individual cases.
  • Type 2 Diabetes Mellitus
    T2DM is characterised by relative insulin deficiency caused by pancreatic β-cells dysfunction and insulin resistance in target organs. It develops over many years and is usually diagnosed in adults.
  • Gestational Diabetes
    Gestational diabetes (GDM) is the third main form, and occurs when pregnant women without a previous history of diabetes develop high blood sugar levels. Risk factors include being overweight, previously having gestational diabetes, a family history of type 2 diabetes, and having polycystic ovarian syndrome. In women with gestational diabetes, blood sugar usually returns to normal soon after delivery.

Fig 2. The immunopathogenesis of T1DMThe Immunopathogenesis of T1DM (Linda, A. D.; et al. the lancet, 2018)

Therapies of Diabetes

  • Hypoglycemic Therapy
    T2DM is a heterogeneous and progressive disease with a variety of causative and potentiating factors. The hyperglycemia of T2DM is often inadequately controlled, hence the need for a wider selection of glucose-lowering treatments.
  • Antibodies Therapy
    Insulin acts by binding to the insulin receptor (INSR) on the cell surface, a process that activates cell signaling. In humans, autoantibodies to the INSR typically bind at the insulin binding site. And these antibodies block insulin binding, causing severe insulin resistance. Antibody therapy could treat diabetes by improving the condition.

Our Service

Diabetes is a field worthy of in-depth research, Ace Therapeutics provides research programs and technical services from pathology to preclinical. Our services include but not limited to the followings.

Features of Our Services

Highly CustomizableHighly Customizable

One-stop ServicesOne-stop Services

High QualitysHigh Quality

Professional TeamProfessional Team

Whether you are performing studies on new or modified medications, insulin alternatives or treatments about diabetes, Ace Therapeutics can support you. We guarantee to deliver our products and results on time. Please feel free to contact us.


  1. Anker S. D.; et al. Empagliflozin in heart failure with a preserved ejection fraction. New England journal of medicine. 2021, 385(16): 1451-1461.
  2. Linda, A. D.; et al. Type 1 diabetes. The lancet. 2018, 391, 2449–62.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Related Services
Related Products
Contact Info
Copyright © Ace Therapeutics. All Rights Reserved.